IL1B and Crouzon syndrome-acanthosis nigricans syndrome: Similarly, adjusting IL-1-INH dosages by increasing the dose at each administration or decreasing the timing between injections have proved to be successful choices in 66.7% of patients treated with ANA or CAN.